- Novo Nordisk began a 450-person clinical trial on August 12 to test two unspecified low doses of its oral Wegovy semaglutide pill against a placebo in patients with a BMI of at least 27 — the WHO “overweight” threshold — marking a deliberate scientific effort to establish the minimum effective dose rather than the maximum tolerable one, which has been the standard approach in obesity drug development.
- The trial reflects a real-world reality that most obesity drug research has not adequately addressed: more than two-thirds of the roughly 5 million patients who have been prescribed the Wegovy pill since its U.S. launch in January are on the two lowest available doses, either because they experience side effects at higher doses, find lower doses effective enough, or choose to microdose for cost or lifestyle reasons.
- Price is a significant driver of dose selection — the two lower doses of the Wegovy pill cost roughly half as much as the two higher doses for self-pay customers, creating a financial incentive for patients and prescribers to remain at lower dose tiers that the existing clinical evidence base, which was optimized for maximum efficacy at high doses, does not fully support or characterize.
- The trial also captures a broader market dynamic: telehealth companies in the United States have been actively marketing GLP-1 medications including Wegovy to people who are not technically obese or even overweight, and formalizing the efficacy and safety profile of low-dose regimens could legitimize a much larger addressable market while also providing Novo Nordisk with the data needed to defend low-dose prescribing against payer and regulatory scrutiny.
What Happened?
Novo Nordisk registered a new clinical trial on August 12 in the U.S. government’s ClinicalTrials.gov database: a 450-person study testing two unspecified low doses of its oral Wegovy semaglutide pill against placebo in patients with a BMI of at least 27. The trial represents a strategic pivot in how the company is approaching its pill formulation’s development program. Standard obesity drug trials have historically aimed to establish the maximum tolerable dose — the ceiling of efficacy — because that data is most persuasive to regulators and prescribers seeking best-in-class weight loss outcomes. Novo is now running a study designed to characterize the floor: how low can patients go and still achieve meaningful weight loss? The answer matters enormously because most real-world Wegovy pill users are already at the lower end of the dose range.
Why It Matters?
The Wegovy pill has been prescribed more than 5 million times since it launched in the United States in January 2026, making it one of the fastest-adopted prescription drugs in recent history. But the clinical evidence supporting the drug was generated primarily at the higher doses that regulators approved — yet BMO Capital Markets analyst Evan Seigerman estimates that more than two-thirds of actual prescriptions are for the two lowest doses. That gap between the clinical evidence base and actual prescribing patterns creates risk for prescribers, patients, and payers: insurers may question reimbursement for doses that lack specific efficacy data, and patients on low doses may be uncertain whether they’re getting meaningful benefit. A formal low-dose efficacy study resolves this uncertainty and could also significantly expand Novo’s market — lower doses at lower prices bring GLP-1 therapy within reach of more patients, including the telehealth microdosing market that currently operates in a clinical gray area.
What’s Next?
Results from the 450-person trial will take at least 12-18 months to generate and publish, meaning the data is unlikely to be available before late 2027 at the earliest. In the interim, the low-dose prescribing pattern will continue to grow organically as patients and physicians make pragmatic decisions based on tolerability and cost. If the trial demonstrates that low doses of oral semaglutide produce statistically and clinically meaningful weight loss even in the overweight (rather than obese) population, it could catalyze a significant expansion of the Wegovy pill’s labeled indication and open up an enormous new prescribing opportunity. Competitors including Eli Lilly — whose injectable retatrutide has been subject to illicit market activity — will be watching closely, as low-dose oral GLP-1 data from Novo could set a competitive benchmark that reshapes the entire obesity drug competitive landscape.
Source: Bloomberg
